Amino acid metabolism related to immune tolerance by MDSCs

International Reviews of Immunology

Volumn 31, Issue 3, 2012, Pages 177-183

  Yang, Baohong ^a   Wang, Xiaomeng ^a   Ren, Xiubao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Amino acid; MDSCs; Tumor induced immune suppression

Indexed keywords

CYSTINE; PHENYLALANINE;

AMINO ACID METABOLISM; BONE MARROW CELL; CELL POPULATION; CELL TYPE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRYPTOPHAN METABOLISM; TUMOR IMMUNITY;

AMINO ACIDS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; MYELOID CELLS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84862094719     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.679989     Document Type: Review

References (48)

1. Finn OJ. Cancer vaccines: between the idea and the reality. Nature Rev Immunol. 2003;3:630-641. (Pubitemid 37328666)
2. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction ofM1macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636-645. (Pubitemid 40094255)
3. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol (Baltimore). 2000;165:779-785. (Pubitemid 30484744)
4. Suzuki E,Kapoor V, JassarAS,Kaiser LR,Albelda SM.Gemcitabine selectively eliminates splenicGr- 1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713-6721. (Pubitemid 41339014)
5. + T cells. J Immunol (Baltimore). 2009;183:937-944.
6. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloidderived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977-983.
7. Angelini G, Gardella S, Ardy M, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A. 2002;99:1491-1496. (Pubitemid 34136520)
8. Rodriguez PC, Ochoa AC. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol. 2006;16:66-72. (Pubitemid 43139710)
9. Mellor AL,Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-774. (Pubitemid 39336293)
10. De Santo C, Salio M, Masri SH, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest. 2008;118:4036-4048.
11. Brys L, Beschin A, Raes G, et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activatedmyeloid cells elicited during helminth infection. J Immunol. 2005;174:6095-6104. (Pubitemid 40663798)
12. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR- 1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007;204:1463-1474. (Pubitemid 46919883)
13. Dranoff G. GM-CSF-secretingmelanoma vaccines. Oncogene. 2003;22:3188-3192.
14. MakarenkovaVP,BansalV,MattaBM,PerezLA,Ochoa JB.CD11b+/Gr-1+myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol. 2006;176:2085-2094. (Pubitemid 43201655)
15. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol. 1999;21:241-252. (Pubitemid 29241776)
16. Zhu B, Bando Y, Xiao S, et al. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol. 2007;179:5228-5237.
17. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233-4244.
18. GabrilovichD, Ishida T,Oyama T, et al.Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-166. (Pubitemid 28544331)
19. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.The Oncologist. 2000;5 (Suppl 1):11-15. (Pubitemid 30225451)
20. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functionalmaturation of dendritic cells. NatureMed. 1996;2:1096-1103. (Pubitemid 26338628)
21. Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of Langerhans cells in tumorbearing animals is the result of defectivematuration fromhemopoietic progenitors. J Immunol(Baltimore). 1998;161:4842-4851. (Pubitemid 28492062)
22. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem/FEBS. 2000;267:6102-6109.
23. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633-1640. (Pubitemid 32994684)
24. Viola A, Bronte V. Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol. 2007;17:309-316. (Pubitemid 47211961)
25. GabrilovichDI,VeldersMP, SotomayorEM,KastWM.Mechanism ofimmune dysfunction incancer mediated by immature Gr-1+ myeloid cells. J Immunol (Baltimore). 2001;166:5398-5406. (Pubitemid 32374159)
26. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem. 1992;200:218-229.
27. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearingmice and improves the effect of vaccination. Cancer Res. 2003;63:4441-4449. (Pubitemid 36951016)
28. Ishii I, Akahoshi N, Yu XN, et al. Murine cystathionine gamma-lyase: complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem J. 2004;381:113-123. (Pubitemid 38932217)
29. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425; author reply 426. (Pubitemid 46142802)
30. Young MR, Wright MA. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bonemarrowcells and diminishes tumor recurrence and metastasis. Cancer Res. 1992;52:6335-6340.
31. GmunderH,Eck HP,DrogeW.Lowmembrane transport activity for cystine inresting andmitogenically stimulated human lymphocyte preparations and human T cell clones. Eur J Biochem/FEBS. 1991;201:113-117.
32. Eagle H,Washington C, Friedman SM.Thesynthesis of homocystine, cystathionine, and cystine by cultured diploid and heteroploid human cells. Proc Natl Acad Sci U S A. 1966;56:156-163.
33. Gmunder H, Eck HP, Benninghoff B, Roth S, Droge W. Macrophages regulate intracellular glutathione levels of lymphocytes: evidence for an immunoregulatory role of cysteine. Cell Immunol. 1990;129:32-46. (Pubitemid 20233611)
34. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70:68-77.
35. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 1996;93:13119-13124. (Pubitemid 26382779)
36. Liu C, Yu S, Kappes J, et al. Expansion of spleenmyeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood. 2007;109:4336-4342. (Pubitemid 46743401)
37. Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med. 2005;202:1627-1633. (Pubitemid 41815868)
38. + effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. J Immunol (Baltimore). 2005;174:6080-6087. (Pubitemid 40663796)
39. Schroder AJ, Pavlidis P, Arimura A, Capece D, Rothman PB. Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes. J Immunol (Baltimore). 2002;168:996-1000. (Pubitemid 34094461)
40. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49-59.
41. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553-1560.
42. Liu CY, Wang YM, Wang CL, et al. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b(+)/CD14 (-)/ CD15 (+)/CD33 (+) myeloid-derived suppressor cellsand CD8 (+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;110:36-45.
43. Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562-6568.
44. Nausch N, Galani IE, Schlecker E, Cerwenka A. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate NK cells. Blood. 2008;112:4080-4089.
45. Schmielau J, Finn OJ. Activated granulocytes and ranulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001;61:4756-4760. (Pubitemid 32691887)
46. Srivastava MK, Bosch JJ,Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients' CD4(+)T cells are activated in vitro byMHCII cell-based vaccines despite the presence ofmyeloid-derived suppressor cells. Cancer Immunol Immunother. 2008;57:1493-1504.
47. Daud AI, Mirza N, Lenox B, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treatedwith adjuvant granulocytemacrophage colony-stimulating factor. J Clin Oncol. 2008;26:3235-3241.
48. Brandau S, Trellakis S, Bruderek K, et al.Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol. 2011 Feb;89(2):311-317. Epub 2010 Nov 24.